About datopotamab deruxtecan
TROP2-directed antibody-drug conjugate
Used for
- Treats certain unresectable or metastatic hormone receptor-positive, HER2-negative breast cancers after prior systemic treatment.
- Treats certain locally advanced or metastatic non-small cell lung cancers after prior systemic treatment.
Usual adult dose
6 mg/kg by intravenous infusion every 3 weeks for breast cancer; 6 mg/kg every 3 weeks for lung cancer, subject to local approval and labeling.
Common side effects
- Mouth sores or inflammation
- Nausea and fatigue
- Hair loss
- Dry eye or other eye problems
Important warnings
- Can cause interstitial lung disease or pneumonitis, sometimes fatal.
- Can cause serious eye problems and severe mouth inflammation.
- Monitor for infusion reactions and low blood counts.
- May harm an unborn baby; effective contraception is required.
Pregnancy
May cause fetal harm. Avoid during pregnancy; effective contraception is recommended during treatment and for 7 months after the last dose.
Breastfeeding
Do not breastfeed during treatment and for 1 month after the last dose.
Interactions
- No major established drug interactions are specified; review all medicines with the oncology team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.